Key facts
- It has raised $10.0M across 1 recorded rounds; the latest was Early Stage VC ($10.0M) in Jan 2026.
- MultiValent Biotherapies has filed 2 Form Ds with the SEC, most recently Mar 2026 ($10.0M sold to 4 investors).
- Status: Privately Held (backing).
Free account
See the evidence behind this price
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for MultiValent Biotherapies
Create free account
No card required
Funding rounds
1 roundsAbout MultiValent Biotherapies
The company is currently operating in Stealth mode.
- Sector
- Business Products and Services (B2B)
- HQ
- Los Altos, CA, United States
- Founded
- 2025
- Ownership
- Privately Held (backing)
PA Mark — not yet priced
MultiValent Biotherapies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in MultiValent Biotherapies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on MultiValent Biotherapies in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.